MA30075B1 - Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale - Google Patents

Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale

Info

Publication number
MA30075B1
MA30075B1 MA31059A MA31059A MA30075B1 MA 30075 B1 MA30075 B1 MA 30075B1 MA 31059 A MA31059 A MA 31059A MA 31059 A MA31059 A MA 31059A MA 30075 B1 MA30075 B1 MA 30075B1
Authority
MA
Morocco
Prior art keywords
treatment
cell growth
abnormal cell
pyrimidine derivatives
mammals
Prior art date
Application number
MA31059A
Other languages
English (en)
Inventor
Joel Thomas Arcari
Samit Kumar Bhattacharya
Arthur Douglas Brosius
Michael Joseph Luzzio
Kendra Louise Nelson
Gonghua Pan
James Alfred Southers Jr
Donn Gregory Wishka
Jun Xiao
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA30075B1 publication Critical patent/MA30075B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)

Abstract

Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale La présente invention concerne un composé de formule (I), ou un de ses sels pharmaceutiquement acceptables, formule dans laquelle Ar représente un groupe de formule (III), et R1, R2, R13, A, K, M, L1, L2, X, Y1, Y2, Q, un de ses sels, où R1, R2, R13, A, K, L1, L2, W, X, Z1, Z2, Y1, Y2, Z1, Z2, M, Q, W, X, m, p et q répondent aux définitions figurant dans le présent mémoire. Ces dérivés de pyrimidine nouveaux sont utiles dans le traitement d'une croissance cellulaire anormale, telle qu'un cancer, chez des mammifères. La présente invention concerne également une méthode d'utilisation de ces composés dans le traitement d'une croissance cellulaire anormale chez des mammifères, notamment des êtres humains, et des compositions pharmaceutiques contenant ces composés.
MA31059A 2005-12-21 2008-06-20 Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale MA30075B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75270805P 2005-12-21 2005-12-21

Publications (1)

Publication Number Publication Date
MA30075B1 true MA30075B1 (fr) 2008-12-01

Family

ID=38038639

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31059A MA30075B1 (fr) 2005-12-21 2008-06-20 Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale

Country Status (30)

Country Link
US (1) US7820648B2 (fr)
EP (1) EP1966207A2 (fr)
JP (1) JP4332590B2 (fr)
KR (1) KR101060051B1 (fr)
CN (1) CN101346380B (fr)
AP (1) AP2008004488A0 (fr)
AR (1) AR058399A1 (fr)
AU (1) AU2006327871A1 (fr)
BR (1) BRPI0620324A2 (fr)
CA (1) CA2634646C (fr)
CR (1) CR10095A (fr)
DO (1) DOP2006000289A (fr)
EA (1) EA014551B1 (fr)
EC (1) ECSP088563A (fr)
GT (1) GT200600517A (fr)
HN (1) HN2006042221A (fr)
IL (1) IL191555A0 (fr)
MA (1) MA30075B1 (fr)
ME (1) MEP0908A (fr)
NL (1) NL2000375C2 (fr)
NO (1) NO20082338L (fr)
PE (1) PE20071138A1 (fr)
RS (1) RS20080272A (fr)
SV (1) SV2008002969A (fr)
TN (1) TNSN08270A1 (fr)
TW (1) TW200736258A (fr)
UA (1) UA89123C2 (fr)
UY (1) UY30051A1 (fr)
WO (1) WO2007072158A2 (fr)
ZA (1) ZA200804488B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2421139T3 (es) 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
WO2008003766A2 (fr) * 2006-07-06 2008-01-10 Boehringer Ingelheim International Gmbh Nouveaux composés
MX2009004426A (es) 2006-10-23 2009-08-12 Cephalon Inc Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met.
DK2146779T3 (en) 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
CN101903357A (zh) 2007-07-17 2010-12-01 里格尔药品股份有限公司 作为pkc抑制剂的环状胺取代的嘧啶二胺
US8461147B2 (en) * 2007-12-03 2013-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
UY31714A (es) * 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
CA2718858A1 (fr) * 2008-03-20 2009-09-24 Boehringer Ingelheim International Gmbh Elaboration regioselective de pyrimidines substituees
CN102124000B (zh) 2008-06-17 2014-09-17 阿斯利康(瑞典)有限公司 吡啶化合物
EP2161259A1 (fr) 2008-09-03 2010-03-10 Bayer CropScience AG 4-haloalkyle-diaminopyrimidines substitués
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
US8729265B2 (en) 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
TWI513694B (zh) 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
BR112012029647A2 (pt) 2010-05-21 2016-08-02 Chemilia Ab novos derivados de pirimidinas
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
WO2012074951A1 (fr) 2010-11-29 2012-06-07 OSI Pharmaceuticals, LLC Inhibiteurs de kinase macrocycliques
MX2013010898A (es) 2011-03-24 2013-12-06 Chemilia Ab Novedoso derivados de la pirimidina.
BR112014013178A2 (pt) 2011-12-09 2017-06-13 Chiesi Farm Spa composto, composição farmacêutica e uso de um composto
EP2794598A1 (fr) 2011-12-23 2014-10-29 Cellzome Limited Dérivés de pyrimidine-2,4-diamine en tant qu'inhibiteurs de kinase
CN103655577A (zh) * 2012-09-20 2014-03-26 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103664957A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
CN105130907B (zh) * 2015-07-29 2018-10-16 沈阳药科大学 嘧啶类化合物及其用途
EP3484528B1 (fr) 2016-07-18 2020-11-25 Janssen Pharmaceutica NV Ligands d'imagerie tep pour la protéine tau
US20200038513A1 (en) * 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
AU2022205713A1 (en) * 2021-01-07 2023-07-27 Ontario Institute For Cancer Research (Oicr) Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof
US12643886B2 (en) 2021-01-07 2026-06-02 Ontario Institute for Cancer Research (OICR), The Governing Council of the University of Toronto, Sinai Health System Isoindolinone aminopyrimidine compounds as inhibitors of NUAK kinases, compositions and uses thereof
KR20240031347A (ko) * 2021-07-01 2024-03-07 에어리 파마슈티컬즈, 인코포레이티드 아제티디닐 피리미딘 및 그의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2003030909A1 (fr) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (fr) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Derives de pyridinyl amino pyrimidine utilises dans le traitement des troubles de l'hyperproliferation
WO2004048343A1 (fr) * 2002-11-28 2004-06-10 Schering Aktiengesellschaft Pyrimidines inhibitrices de chk-, pdk- et de akt, production et utilisation de ces composes comme agents pharmaceutiques
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
EP1590334B1 (fr) * 2003-01-30 2009-08-19 Boehringer Ingelheim Pharmaceuticals Inc. Derives de 2,4-diaminopyrimidine utiles en tant qu'inhibiteurs de l'enzyme pkc-theta
EP1758887A1 (fr) 2004-05-14 2007-03-07 Pfizer Products Incorporated Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
EA200601796A1 (ru) * 2004-05-14 2007-04-27 Пфайзер Продактс, Инк. Пиримидиновые производные для лечения аномального клеточного роста

Also Published As

Publication number Publication date
DOP2006000289A (es) 2007-07-31
RS20080272A (sr) 2009-07-15
EA200801287A1 (ru) 2008-10-30
CN101346380A (zh) 2009-01-14
ZA200804488B (en) 2009-05-27
NO20082338L (no) 2008-06-25
NL2000375C2 (nl) 2008-01-03
AR058399A1 (es) 2008-01-30
JP4332590B2 (ja) 2009-09-16
TW200736258A (en) 2007-10-01
US20080234303A1 (en) 2008-09-25
BRPI0620324A2 (pt) 2011-11-08
NL2000375A1 (nl) 2007-06-25
US7820648B2 (en) 2010-10-26
KR20080077026A (ko) 2008-08-20
UY30051A1 (es) 2007-07-31
JP2009520807A (ja) 2009-05-28
EP1966207A2 (fr) 2008-09-10
WO2007072158A3 (fr) 2007-12-27
CN101346380B (zh) 2012-02-29
TNSN08270A1 (fr) 2009-10-30
CR10095A (es) 2008-07-17
MEP0908A (xx) 2010-02-10
AP2008004488A0 (en) 2008-06-30
ECSP088563A (es) 2008-07-30
EA014551B1 (ru) 2010-12-30
WO2007072158A2 (fr) 2007-06-28
WO2007072158A8 (fr) 2008-08-14
HN2006042221A (es) 2010-01-18
AU2006327871A1 (en) 2007-06-28
PE20071138A1 (es) 2007-12-29
CA2634646A1 (fr) 2007-06-28
UA89123C2 (ru) 2009-12-25
SV2008002969A (es) 2010-08-17
IL191555A0 (en) 2008-12-29
CA2634646C (fr) 2012-04-10
KR101060051B1 (ko) 2011-08-29
GT200600517A (es) 2007-09-13

Similar Documents

Publication Publication Date Title
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale
TN2009000544A1 (fr) Derives de benzimidazole
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA67365B1 (fr) Dérivés de benzisoxazole sulfonamide
MA29926B1 (fr) Derives de pyrazine
MA27754A1 (fr) Pyrimidinones substituees
MA28747B1 (fr) Dérivés de pyridine
MA30403B1 (fr) Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
TW200607801A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005037825A3 (fr) Inhibiteurs de la proteine kinase
MA27568A1 (fr) Derives de pyrrolopyrimidine
TN2009000450A1 (fr) Derives de pyridine
TNSN07275A1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
TNSN04156A1 (fr) Pyridinones substituees servant de modulateurs de la map-kinase p38
WO2004037181A3 (fr) Inhibiteurs de dipeptidyl peptidase iv a base de glycinenitrile et procedes correspondants
MA31873B1 (fr) Inhibiteurs de la peptide déformylase
MA32009B1 (fr) Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux
MA28270A1 (fr) Pyrido [2, 3-D] pyrimidine-2, 4-diamines servant d'inhibiteurs de PDE 2
MXPA06013164A (es) Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
MA27775A1 (fr) Composes organiques
TNSN06370A1 (fr) Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
TNSN07400A1 (fr) Derives d'aminoacides
MA27716A1 (fr) 4-aminopyrimidine-5-one
MA27930A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4